Skip to content
mapperlab
← Dashboard
Stock

ELDN

ELEDON PHARMACEUTICALS, INC.
Latest close $3.582 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
2
27 funds tracked
Ever held
5
Current + past
New this quarter
0
Exited this quarter
1

Marquee-fund ownership over time

Aug 9, 2024May 15, 2025Feb 17, 2026May 15, 2026
Now
2

This quarter's activity

New positions opened

None.

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies$2.62$3.58+37%
AQR Capital Management$2.11$3.58+70%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
Millennium Management 2× in & out→ $3.80+80%
Citadel Advisors→ $1.76-61%
Point72 Asset Management→ $2.89-36%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at Eledon Pharmaceuticals, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
6
Filings · last 90d
6
Total on file
165
Recent SEC buffer
Most recent
Jan 16, 2026

30d / 90d windows measured from Jan 16, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 165 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · ELEDON PHARMACEUTICALS, INC.

Annual figures sourced directly from ELEDON PHARMACEUTICALS, INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$0
FY2016
Net income
-$45.62M
FY2025-26% YoY
EPS (diluted)
$-0.5200
FY2025+21% YoY
Free cash flow(?)
-$62.34M
FY2025-32% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for Eledon Pharmaceuticals, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
AQR Capital ManagementQ1 2026open$2.11$3.58+70%
Millennium ManagementQ1 2026Q2 2026$2.11$3.80+80%
Citadel AdvisorsQ1 2025Q4 2025$4.53$1.76-61%
Millennium ManagementQ1 2025Q4 2025$4.53$1.76-61%
Point72 Asset ManagementQ1 2025Q2 2025$4.53$2.89-36%
Renaissance TechnologiesQ3 2024open$2.62$3.58+37%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.